T45 Labs and the art of arriving second

A patient can have persistent chest pain without a blockage in the heart’s major arteries. The trouble may lie in the smaller vessels. For a device developer, that is a particularly awkward problem: the familiar intervention does not necessarily address the part of the system that needs attention. VahatiCor, one of T45 Labs’ portfolio companies, is investigating a coronary sinus implant for precisely this territory. It is a useful introduction to how T45 thinks.

The second-mover wager

T45 Labs is a cardiovascular incubator and investment platform in Santa Clara. Founded in 2022, it develops minimally invasive technologies with physicians and entrepreneurs. Its declared ambition is to build acquisition-ready companies. The adjective matters. A promising invention and a company that another manufacturer can evaluate and buy occupy different places on the development road.

The firm calls its method “best follower.” Enter after the clinical need has been validated. Refine an early concept. Pay attention to outcomes, usability and cost. Then assemble clinical proof. The appeal is straightforward: a known market gives the team a starting point, while an unresolved limitation gives it something specific to improve. Being second still requires an original answer.

“Design with outcomes, ease, and cost in mind”

T45 Labs’ published strategy

An engineer with a fund

Founder and managing partner Marwan Berrada-Sounni previously led product development at the Cleveland Clinic Foundation and served on the Global Cardiovascular Innovation Center’s commercialization funding committee. His background joins two activities that young medical companies must repeatedly reconcile: making something work and persuading someone to finance the next test.

T45 puts those activities inside the same operating model. Its leadership includes clinical affairs, regulatory and quality specialists alongside commercial and investment experience. Chief medical director Rishi Puri is an interventional cardiologist at Cleveland Clinic. The firm’s public materials emphasize sustained involvement from research through clinical development. Its March 2025 fund announcement described a 10,000-square-foot facility for portfolio device work.

For a physician with a device concept, the offer is practical: access to people who can develop it, organize its studies and plan its regulatory path. For an investor, the proposition is a portfolio of cardiovascular programs advancing toward defined milestones. The shared team is part of what the capital buys.

Four ways into the heart

Advanced NanoTherapies is developing SirPlux Duo, a drug-coated balloon that delivers paclitaxel and sirolimus through a nanoparticle coating. The technology is exclusively licensed from Cleveland Clinic. Its ambition is local drug delivery without leaving a permanent implant. Here, T45’s refinement thesis appears in the coating and delivery mechanism within an existing category.

VahatiCor addresses a different limitation. Its investigational A-FLUX Reducer System is a self-expanding device delivered to the coronary sinus, designed to influence blood flow through the heart’s smaller vessels. In June 2026, the company announced its first U.S. patient in the SERRA-I early feasibility study at Yale-New Haven Hospital. That is a clinical investigation milestone, with broader questions still ahead.

NuevoSono makes workflow part of the engineering problem. It is developing compact, wireless intravascular ultrasound, or IVUS, intended to dispense with the bulky console and simplify setup in the catheterization lab. Planned AI features would assist interpretation, subject to validation and regulatory clearance. A January 2026 partnership with SUPERWISE brings AI governance and operational controls into those plans.

Then there is Mitria Medical, which partnered with T45 in September 2026. Its investigational Subvalvular Spacer supports a displaced mitral valve leaflet from beneath, aiming to help the valve close while maintaining its opening. The announcement reported six implant recipients and named Berrada-Sounni CEO. T45’s remit includes financing, operations, development and clinical and regulatory strategy.

The expensive part is proving it

In March 2025, T45 announced the close of its oversubscribed $25 million Fund-I. The fund supports portfolio development and clinical research. Its successor, Fund-II, is marketed with a $50 million target, with the homepage pointing to a year-end 2026 close. A target describes the next fundraising ambition; it does not establish cash already raised.

Portfolio companies also raise money independently. VahatiCor announced a $23 million Series B in November 2025. Advanced NanoTherapies announced more than $31 million in June 2026, with T45 Fund participation. The latter financing supports manufacturing and U.S. regulatory and clinical work. Each figure belongs to a particular financing and a particular set of next steps.

This distinction helps explain the business. T45 wants returns from strategic acquisitions after development risk has been reduced. Its public position is a specialist company builder; Shifamed offers a comparable medtech model. Founders can also assemble an independent company and raise venture capital themselves. T45’s case rests on the usefulness of its combined operating support.

The sequence also changes what progress looks like. A manufacturer considering an acquisition needs evidence it can examine: a device design, a study population, a regulatory plan. T45 organizes its public story around those elements. For someone evaluating the platform, a useful question is which uncertainty each new milestone removes. An early patient experience can inform the next study without settling whether a technology will work across a wider population.

Borrow the sequence

The transferable idea is the order of decisions. Pick a problem physicians already recognize. Identify a concrete improvement. Decide which experiment would make the next investment decision better informed. Then organize money and expertise around that experiment. T45’s portfolio makes those choices tangible: drug delivery, small-vessel disease, imaging workflow and valve mechanics.

The approach depends on clinical evidence supporting the improvement, enough capital to reach meaningful milestones and buyers who value the result. T45’s featured devices remain investigational or under development. The company’s progress is therefore best read through studies and financing milestones. Arriving second creates an opportunity. The work is making the improvement hold up.